Home › Research › Tau biomarkers
Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid
Rosenberg A, Solomon A, Jelic V, Hagman G, Bogdanovic N, Kivipelto M.. Alzheimer's research & therapy, 2019-12-05
Topic: Amyloid, tau and blood-test diagnosis
Background Determination of β-amyloid (Aβ) positivity and likelihood of underlying Alzheimer's disease (AD) relies on dichotomous biomarker cut-off values. Individuals with mild cognitive impairment (MCI) and Aβ within the normal range may still have a substantial risk of developing dementia, primarily of Alzheimer type. Their prognosis, as well as predictors of clinical progression, are not fully understood.
Key findings
- Individuals with mild cognitive impairment (MCI) and Aβ within the normal range may still have a substantial risk of developing dementia, primarily of Alzheimer type.
- Their prognosis, as well as predictors of clinical progression, are not fully understood.
- The aim of this study was to explore the associations of cerebrospinal fluid (CSF) biomarkers (Aβ42, total tau, phosphorylated tau) and other characteristics, including modifiable vascular factors, with the risk of progression to dementia among patients with MCI and normal CSF Aβ42.
- Methods Three hundred eighteen memory clinic patients with CSF and clinical data, and at least 1-year follow-up, were included.
Why it matters
This study explored which cerebrospinal fluid biomarkers and other characteristics, including modifiable vascular factors, predict progression to dementia in memory clinic patients with mild cognitive impairment whose amyloid level was in the normal range. It is about prognosis and risk factors, not about a treatment or cure.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer's research & therapy) |
| Journal's citation record | 1 / 4 | Alzheimer s Research & Therapy: journal h-index 146 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 34 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.8 citations a year over 9 year(s) since 2019 |
| Impact for its field and year | 2 / 6 | Cited 2.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 14 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Miia Kivipelto: h-index 107 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Imperial College London: institution h-index 1,744 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 31805990) |
| Free to read | 2 / 2 | Free to read |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s13195-019-0557-1
- PubMed: 31805990
- Original source →
- Free full text: Alzheimer s Research & Therapy →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Rosenberg, A., Solomon, A., Jelic, V., Hagman, G., Bogdanovic, N., & Kivipelto, M. (2019). Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid. Alzheimer's research & therapy. https://doi.org/10.1186/s13195-019-0557-1
Vancouver
Rosenberg A, Solomon A, Jelic V, Hagman G, Bogdanovic N, Kivipelto M. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid. Alzheimer's research & therapy. 2019. doi:10.1186/s13195-019-0557-1. PMID: 31805990.
BibTeX
@article{rosenberg2019-31805990,
author = {Rosenberg, A. and Solomon, A. and Jelic, V. and Hagman, G. and Bogdanovic, N. and Kivipelto, M.},
title = {{Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid}},
journal = {Alzheimer's research \& therapy},
year = {2019},
doi = {10.1186/s13195-019-0557-1},
pmid = {31805990},
url = {https://doi.org/10.1186/s13195-019-0557-1}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 46.
Related studies in Tau biomarkers
Also tagged “biomarkers”
821 studies in the library carry the topic tag “biomarkers”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.